Clinical Trials
19 trialsNCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT02616965 2025-04-04
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT04774068 2025-01-17
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT01947140 2022-11-23
PDX+Romi
Columbia University
Phase 1/2 Completed
NCT02181218 2020-11-17
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
Phase 1 Completed
NCT01902225 2020-06-09
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT01445340 2019-12-17
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT01738594 2019-08-29
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
Phase 1 Terminated
NCT02061449 2018-12-24
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NYU Langone Health
Phase 1 Terminated
NCT00007345 2017-05-16
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02296398 2016-03-11
Long-term Use of Romidepsin in Patients With CTCL
Northwestern University
Completed
NCT00019318 2015-04-29
Depsipeptide in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed